If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

21 Dec 2015 18:22

RNS Number : 8050J
GW Pharmaceuticals PLC
21 December 2015
 



GW Pharmaceuticals PLC Director/PDMR Shareholding

21 December 2015

 

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

 

Cambridge, UK, 21 December 2015: GW Pharmaceuticals (AIM: GWP, NASDAQ:GWPH) hereby provides notification that the Company has been notified of the following series of transactions in the shares of GW Pharmaceuticals plc.

 

On 18 December 2015 the Company was notified that on 17 December 2015 Mr Cabot Brown, a non-executive Director of the Company, purchased 600 American Depository Shares, or ADS (equivalent to 7,200 ordinary 0.1 pence shares) of GW Pharmaceuticals plc, at a price of $68.864 per ADS (equivalent to 384 pence per share).

 

Following this notification Mr Brown's interest in the shares of GW Pharmaceuticals plc is 7,200 ordinary 0.1 pence shares (equivalent to 600 ADSs), representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Mr. Chris Tovey, a Director and Chief Operating Officer of the Company, exercised options to acquire 24,000 ordinary 0.1 pence shares (equivalent to 2,000 ADSs) of GW Pharmaceuticals plc. These options had an exercise price of 0.1 pence per share. The Company has been notified that on 18 December 2015 these shares, representing less than 0.1% of shares in issue, were converted to 2,000 ADSs and immediately sold at an average price of $67.6275 per ADS (equivalent to 378 pence per share).

 

Following these transactions, Mr. Tovey's beneficial interested in the Company's ordinary 0.1 pence shares is 2,500 shares, representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Dr. Geoffrey Guy, a Director and Chairman of the Company, exercised options to acquire 1,369,848 ordinary 0.1 pence shares (equivalent to 114,154 ADSs) of GW Pharmaceuticals plc. These options had a weighted average exercise price of 41 pence per ordinary 0.1 pence share. The Company has been notified that (1) on 18 December 2015, 1,065,936 of these shares were converted to 88,828 ADSs and immediately sold at an average price of $67.50 per ADS (equivalent to 377 pence per share) and (2) earlier today a further 10,309 ADSs (equivalent to 123,708 ordinary 0.1 pence shares) were sold at an average price of $67.32 per ADS (equivalent to 376 pence per share). Exercise of these options results in an immediate UK income tax liability for Dr. Guy necessitating the immediate sale of a significant number of the resulting shares. In addition, we have been notified that earlier today 6,000 ordinary 0.1 pence shares held by Dr Guy's personal pension scheme were sold at an average price of 366 pence per share.

 

Following these transactions, Dr. Guy's notifiable interest in the ordinary 0.1 pence shares of the Company has increased by 174,204 shares to 14,297,852 shares, representing 5.4% of the Company's current issued share capital.

 

The total number of shares outstanding in the Company is 262,574,021 ordinary 0.1 pence shares.

 

For further information, please contact:

 

GW Pharmaceuticals plc

Adam George, Company Secretary

+44 (0)1980 557 000

Peel Hunt LLP (UK NOMAD)

James Steel

+44 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFFTFLLLFIE
Date   Source Headline
8th Sep 20152:37 pmRNSBlock Listing Application
17th Aug 20159:14 amRNSBlocklisting Interim Review
6th Aug 201512:28 pmRNSThird Quarter 2015 Financial Results
6th Aug 201511:45 amRNSFDA Fast Track and EMA Orphan Designations for CBD
23rd Jul 201512:00 pmRNSNotice of Results
16th Jul 20154:15 pmRNSAppointment of Director
16th Jul 201510:40 amRNSHolding(s) in Company
9th Jul 20154:57 pmRNSHolding(s) in Company
9th Jul 20154:24 pmRNSHolding(s) in Company
7th Jul 20153:23 pmRNSHolding(s) in Company
30th Jun 20157:00 amRNSDirector/PDMR Shareholding
24th Jun 20155:56 pmRNSDirector/PDMR Shareholding
12th Jun 20155:39 pmRNSDirector/PDMR Shareholding
11th Jun 201512:00 pmRNSSecond Ph3 Pivotal Study of Epidiolex in LGS
1st Jun 201510:19 amRNSBlock Listing Application
1st Jun 20157:54 amRNSHolding(s) in Company
1st Jun 20157:53 amRNSHolding(s) in Company
29th May 201511:13 amRNSHolding(s) in Company
19th May 201512:00 pmRNSAppoints US Executive; Relocates CEO to US
15th May 20155:43 pmRNSPurchase of Additional American Depositary Shares
11th May 20153:00 pmRNSPresenting at BAML 2015 Healthcare Conference
11th May 201512:00 pmRNSHalf Yearly Report
11th May 201512:00 pmRNSInitiates Ph3 Pivotal Study of Epidiolex in LGS
11th May 201511:45 amRNSHolding(s) in Company
11th May 201511:45 amRNSHolding(s) in Company
8th May 20154:22 pmRNSHolding(s) in Company
6th May 201512:00 pmRNSNotice of Results
6th May 201512:00 pmRNSInitiates Phase 2 Trial of CBDV in Epilepsy
6th May 20157:01 amRNSClosing of U.S. Public Offering of ADSs
1st May 20153:28 pmRNSHolding(s) in Company
1st May 20157:30 amRNSHolding(s) in Company
29th Apr 20157:00 amRNSPricing of U.S. Public Offering of ADSs
28th Apr 20157:00 amRNSProposed Public Offering of ADSs
27th Apr 201512:00 pmRNSUS Patent Allowance for Use of Cannabidivarin
24th Apr 201512:00 pmRNSOrphan Drug Designation for CBD in NHIE
23rd Apr 20157:00 amRNSNew Physician Reports of Epidiolex Treatment
21st Apr 201512:00 pmRNSStarts 2nd Ph 3 Epidiolex Trial in Dravet Syndrome
14th Apr 20157:00 amRNSNew Epidiolex Data Released by AAN
1st Apr 20152:03 pmRNSHolding(s) in Company
31st Mar 201512:00 pmRNSStarts Ph 3 Trial for Epidiolex in Dravet Syndrome
17th Mar 20155:18 pmRNSHolding(s) in Company
17th Mar 20155:15 pmRNSHolding(s) in Company
25th Feb 201512:00 pmRNSPresenting at Upcoming Investor Conferences
17th Feb 20153:25 pmRNSBlocklisting Interim Review
16th Feb 20153:52 pmRNSHolding(s) in Company
16th Feb 20153:48 pmRNSHolding(s) in Company
9th Feb 20155:31 pmRNSDirector/PDMR Shareholding
5th Feb 20152:25 pmRNSResult of AGM
5th Feb 201512:00 pmRNSPresents at Leerink Global Healthcare Conference
4th Feb 201512:01 pmRNS1st Quarter Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.